Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14191)	11/17/2004 6:19:11 PM
From: Arthur Radley	Respond to of 52153

I guess I wasn't clear as to why they haven't gotten the myeloma approval. As mentioned they got it approved for leprosy and therefore got the off-label use for this indication without the travails of a phase testing program. That is why I stated they were in the "cat-bird" seat, because they are getting the bulk of revenues by off-label usuage and have avoided the expense of trials. I still think the non-proprietary issues plays into other companies avoiding the drug and the expense of trials. As for the investigation issue...I would hope that something is being done with the gouging issue that allows them to charge $30.00 to a cancer patient whereas the same pill they sell for leprosy at $2.00. Another company I have a problem with is MEDI. Last year they couldn't give away their nasal flu spray...so this year they cut the price in half. Does this mean that in 2003 their pricing allowed them to make a nice profit and when it doesn't sell they can cut the price in half and NOT make a profit?